AR031094A1 - Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen - Google Patents
Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienenInfo
- Publication number
- AR031094A1 AR031094A1 ARP010100730A ARP010100730A AR031094A1 AR 031094 A1 AR031094 A1 AR 031094A1 AR P010100730 A ARP010100730 A AR P010100730A AR P010100730 A ARP010100730 A AR P010100730A AR 031094 A1 AR031094 A1 AR 031094A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- useful
- compounds
- alkyl
- combinations containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos derivados de anilina que son utiles como ligandos para los receptores de la tiroides, los cuales tienen la formula general (1) en la cual: X es oxígeno (-O-), azufre (-S-), carbonilo (-CO-), metileno (-CH2-), o -NH-; Y es -(CH2)n- donde n es un entero de 1 a 5, o -C=C- caracterizado porque puede ser cis o trans; R1 es halogeno, trifluorometilo, o alquilo C1-6 o cicloalquilo C3-7; R2 y R3 son los mismo o diferentes y son hidrogeno, halogeno, alquilo C1-4 o cicloalquilo C3-6, al menos uno de R2 y R3 son diferentes de hidrogeno; R4 es hidrogeno o alquilo inferior; R5 es hidrogeno o alquilo inferior; R6 es ácido carboxílico, o un éster del mismo, o un profármaco del mismo; R7 es hidrogeno o un grupo alcanoilo o un aroilo. Dichos compuestos son utiles para prevenir, inhibir o tratar un padecimiento asociado con la disfuncion del metabolismo, o que es dependiente de la expresion de un gen regulado por T3. Los ejemplos de tales padecimientos asociados con la disfuncion del metabolismo o que son dependientes de la expresion de un gen regulado T3 incluyen, la obesidad, hipercolesterolemia, arteroesclerosis, arritmias cardiacas, depresion, osteoporosis, hipotiroidismo, gota, cáncer de la tiroides así también como glaucoma, insuficiencia cardiaca congestiva y alteraciones de la piel. También se describen las composiciones y combinaciones farmacéuticas que contienen dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18322300P | 2000-02-17 | 2000-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031094A1 true AR031094A1 (es) | 2003-09-10 |
Family
ID=22671959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100730A AR031094A1 (es) | 2000-02-17 | 2001-02-16 | Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6800605B1 (es) |
| EP (1) | EP1257526B1 (es) |
| JP (1) | JP4629294B2 (es) |
| KR (1) | KR100740383B1 (es) |
| CN (1) | CN1216857C (es) |
| AR (1) | AR031094A1 (es) |
| AT (1) | ATE295348T1 (es) |
| AU (2) | AU2001230929B2 (es) |
| BR (1) | BR0108134A (es) |
| CA (1) | CA2400486C (es) |
| CO (1) | CO5271672A1 (es) |
| CZ (1) | CZ20022771A3 (es) |
| DE (1) | DE60110753T2 (es) |
| DK (1) | DK1257526T3 (es) |
| EG (1) | EG25009A (es) |
| ES (1) | ES2242723T3 (es) |
| HK (1) | HK1047925B (es) |
| HU (1) | HUP0301777A3 (es) |
| IL (2) | IL150449A0 (es) |
| MX (1) | MXPA02007929A (es) |
| MY (1) | MY124534A (es) |
| NO (1) | NO329639B1 (es) |
| NZ (1) | NZ520023A (es) |
| PE (1) | PE20020767A1 (es) |
| PL (1) | PL201790B1 (es) |
| PT (1) | PT1257526E (es) |
| RU (1) | RU2260586C2 (es) |
| UY (1) | UY26581A1 (es) |
| WO (1) | WO2001060784A1 (es) |
| ZA (1) | ZA200206072B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| DE10131462A1 (de) * | 2001-06-29 | 2003-01-09 | Bayer Ag | Phenol-Derivate |
| US6806381B2 (en) | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
| EP1448512A1 (en) * | 2001-11-17 | 2004-08-25 | NeuroSearch A/S | Prodrugs of antidepressants and their use for treating depressions |
| GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
| TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
| JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
| CN103664802B (zh) * | 2003-08-14 | 2015-08-05 | 阿雷生物药品公司 | 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 |
| US7501427B2 (en) * | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| GB0406378D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| GB0606212D0 (en) * | 2006-03-28 | 2006-05-10 | Karobio Ab | Pharmaceutical compositions |
| GB0606201D0 (en) * | 2006-03-28 | 2006-05-10 | Karobio Ab | Improved crytalline material |
| US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| GB0724478D0 (en) * | 2007-12-14 | 2008-01-30 | Karobio Ab | Pharmaceutical compositions |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| US8922530B2 (en) * | 2010-01-06 | 2014-12-30 | Apple Inc. | Communicating stylus |
| EP2609910A1 (en) | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Formulations of eprotirome |
| PL2695611T3 (pl) | 2012-08-06 | 2015-03-31 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6982004B2 (ja) * | 2016-05-18 | 2021-12-17 | オレゴン ヘルス アンド サイエンス ユニバーシティ | ソベチロム誘導体 |
| KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
| EP3634426A4 (en) | 2017-06-05 | 2021-04-07 | Viking Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| AU2019397067A1 (en) * | 2018-12-12 | 2021-07-22 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| JP7445996B2 (ja) | 2019-02-21 | 2024-03-08 | ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド | 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用 |
| US11667606B2 (en) | 2019-03-01 | 2023-06-06 | Autobahn Therapeutics, Inc. | Thyromimetics |
| AU2021283577A1 (en) | 2020-06-02 | 2023-01-19 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Novel thyroid hormone β receptor agonist |
| WO2023177667A1 (en) * | 2022-03-16 | 2023-09-21 | Brii Biosciences, Inc. | Thyroid hormone receptor agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1078582B (de) * | 1958-10-29 | 1960-03-31 | Hoechst Ag | Verfahren zur Herstellung substituierter Thyropropionsaeuren |
| JPS6061747A (ja) * | 1983-09-16 | 1985-04-09 | Konishiroku Photo Ind Co Ltd | 熱現像感光材料 |
| ES2108855T3 (es) | 1992-07-21 | 1998-01-01 | Ciba Geigy Ag | Derivados de acido oxamico como agentes hipocolesteremicos. |
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| ATE272609T1 (de) | 1999-03-01 | 2004-08-15 | Pfizer Prod Inc | Oxamsäure und deren derivate als liganden der thyroid-rezeptoren |
| PT1033364E (pt) | 1999-03-01 | 2005-07-29 | Pfizer Prod Inc | Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide |
| CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
| DK1088819T3 (da) | 1999-09-30 | 2005-09-12 | Pfizer Prod Inc | 6-azauracilderivater som thyroidreceptorligander |
| US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| AP2002002634A0 (en) * | 2000-03-31 | 2002-09-30 | Pfizer Prod Inc | Malonamic Acids And Derivatives Thereof As Thyroid Receptor Ligands. |
| AU4884701A (en) * | 2000-05-12 | 2001-11-20 | Kissei Pharmaceutical Co. Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and usethereof |
| JP4225791B2 (ja) * | 2001-05-18 | 2009-02-18 | キッセイ薬品工業株式会社 | 肝癌の予防または再発抑制剤 |
| TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
-
2001
- 2001-01-12 PL PL366149A patent/PL201790B1/pl not_active IP Right Cessation
- 2001-01-12 BR BR0108134-9A patent/BR0108134A/pt not_active Application Discontinuation
- 2001-01-12 MX MXPA02007929A patent/MXPA02007929A/es active IP Right Grant
- 2001-01-12 HU HU0301777A patent/HUP0301777A3/hu unknown
- 2001-01-12 RU RU2002123349/04A patent/RU2260586C2/ru not_active IP Right Cessation
- 2001-01-12 NZ NZ520023A patent/NZ520023A/en not_active IP Right Cessation
- 2001-01-12 CA CA2400486A patent/CA2400486C/en not_active Expired - Fee Related
- 2001-01-12 ES ES01903064T patent/ES2242723T3/es not_active Expired - Lifetime
- 2001-01-12 CZ CZ20022771A patent/CZ20022771A3/cs unknown
- 2001-01-12 IL IL15044901A patent/IL150449A0/xx active IP Right Grant
- 2001-01-12 AU AU2001230929A patent/AU2001230929B2/en not_active Ceased
- 2001-01-12 JP JP2001559838A patent/JP4629294B2/ja not_active Expired - Fee Related
- 2001-01-12 CN CN018050689A patent/CN1216857C/zh not_active Expired - Fee Related
- 2001-01-12 AU AU3092901A patent/AU3092901A/xx active Pending
- 2001-01-12 KR KR1020027010684A patent/KR100740383B1/ko not_active IP Right Cessation
- 2001-01-12 PT PT01903064T patent/PT1257526E/pt unknown
- 2001-01-12 EP EP01903064A patent/EP1257526B1/en not_active Expired - Lifetime
- 2001-01-12 DE DE60110753T patent/DE60110753T2/de not_active Expired - Lifetime
- 2001-01-12 DK DK01903064T patent/DK1257526T3/da active
- 2001-01-12 WO PCT/US2001/001204 patent/WO2001060784A1/en active IP Right Grant
- 2001-01-12 AT AT01903064T patent/ATE295348T1/de active
- 2001-01-16 US US09/761,050 patent/US6800605B1/en not_active Expired - Lifetime
- 2001-01-31 MY MYPI20010445A patent/MY124534A/en unknown
- 2001-02-14 UY UY26581A patent/UY26581A1/es not_active Application Discontinuation
- 2001-02-14 EG EG20010132A patent/EG25009A/xx active
- 2001-02-15 CO CO01012101A patent/CO5271672A1/es not_active Application Discontinuation
- 2001-02-16 AR ARP010100730A patent/AR031094A1/es active IP Right Grant
- 2001-02-16 PE PE20010001762002000058A patent/PE20020767A1/es not_active Application Discontinuation
-
2002
- 2002-06-27 IL IL150449A patent/IL150449A/en not_active IP Right Cessation
- 2002-07-30 ZA ZA200206072A patent/ZA200206072B/en unknown
- 2002-08-16 NO NO20023895A patent/NO329639B1/no not_active IP Right Cessation
-
2003
- 2003-01-03 HK HK03100094.2A patent/HK1047925B/zh not_active IP Right Cessation
-
2004
- 2004-08-30 US US10/930,360 patent/US7109164B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031094A1 (es) | Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen | |
| ES2144412T3 (es) | Derivados de bencimidazoles como antagonistas de 5-ht1a y 5ht2. | |
| ATE370117T1 (de) | Benzamidliganden für den thyroid-rezeptor | |
| AR061644A1 (es) | Derivados de benzofurano | |
| PT1000008E (pt) | Novos ligandos do receptor da tiroide e processo | |
| GT200800058A (es) | Diarilurea para el tratamiento de hipertensión pulmonar | |
| PE20061013A1 (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| PE20011264A1 (es) | Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento | |
| MX2021003585A (es) | Composicion para el cuidado personal que comprende compuesto organico solido insoluble en agua. | |
| ATE340795T1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
| PE20000127A1 (es) | Derivado de bencenosulfonamida | |
| ES2721552T3 (es) | Composiciones de aislamiento libres de plomo mejoradas que contienen polímeros de metaloceno | |
| PE20060557A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1 | |
| AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
| PE83999A1 (es) | Azetidinas | |
| BR0206495A (pt) | Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato | |
| ATE253616T1 (de) | Dispersionen von optischen aufhellern | |
| ATE469159T1 (de) | Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten | |
| GT200000197A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. | |
| PE20040682A1 (es) | Derivados de ciclobutano como antagonistas de nk1 | |
| AR042909A1 (es) | Ligandos de anilida substituidos por el receptor de tiroides | |
| BRPI0509084A (pt) | composição aquosa, método de tratamento, e, lata pulverizadora | |
| MX2007005566A (es) | Sulfamidas como antagonistas de receptor de endotelina para el tratamiento de enfermedades cardiovasculares. | |
| AR012260A1 (es) | Composicion que comprende un polimero que contiene halogeno y una composicion estabilizadora que comprende un mercaptano bloqueado y unsinergista | |
| PE57499A1 (es) | Compuestos analogos a la talidomida elegidos de la clase de las piperidin-2,6-dionas y un procedimiento para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |